Convalescent plasma in high-risk children with SARS-CoV-2

Phase 1, open-label trial of COVID-19 convalescent plasma in Coronavirus Disease 2019 (COVID-19), sponsored by University of California, Los Angeles. Primary endpoints: Cumulative incidence of Grade 3 and Grade 4 adverse events at 28 days and Cumulative incidence of serious adverse events at 28 days. Status: unknown.